All In Biotech

Free tool

FAERS Monitor: Accolate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020547 or its brand name (Accolate, Zafirlukast). Reports on generic versions are filed under their own applications.

Reports

907

Serious

477

53% of reports

Hospitalization

211

Death reported

44

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea110
  • asthma96
  • fatigue87
  • drug ineffective65
  • cough56
  • nausea51
  • pruritus49
  • off label use48
  • wheezing48
  • headache47
  • rash47
  • pneumonia46
  • dizziness44
  • pain43
  • asthenia42

Reports by year received

View as table
YearReports
200418
200510
20067
20079
200813
200914
201015
201114
201227
201325
201432
201538
201677
201751
201860
201951
202064
202168
202256
202353
202467
202583
202655

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,252 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
asthmaSignal9619.716.31,694
wheezingSignal4818.814.3792
coughSignal564.63.6158
dyspnoeaSignal1104.53.8305
pneumoniaSignal463.32.572
pruritusSignal493.02.363
fatigueSignal872.62.187
astheniaSignal422.61.940
rashSignal472.51.942
dizzinessSignal442.01.523
headache471.71.314
pain431.61.210
nausea511.51.18
off label use481.31.03
drug ineffective651.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.